DelveInsight’s, “Type 2 Diabetes Mellitus Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Type 2 Diabetes mellitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Type 2 Diabetes pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Type 2 Diabetes NDA approvals (if any), and product development activities comprising the technology, Type 2 Diabetes Mellitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Type 2 Diabetes Pipeline Report
To explore more information on the latest breakthroughs in the Type 2 Diabetes Pipeline treatment landscape of the report, click here @ Type 2 Diabetes Pipeline Outlook
Type 2 Diabetes Overview
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. Diabetes mellitus are of three types Type1, Type 2 and Gestational Diabetes.
Recent Breakthroughs of Type 2 Diabetes Treatment Landscape
For further information, refer to the detailed Type 2 Diabetes Unmet Needs, Type 2 Diabetes Market Drivers, and Type 2 Diabetes Market Barriers, click here for Type 2 Diabetes Ongoing Clinical Trial Analysis
Type 2 Diabetes Emerging Drugs Profile
Sotagliflozin is an orally-delivered small molecule compound that we are developing for the treatment of heart failure and type 1 and type 2 diabetes. The scientists identified the targets of sotagliflozin, sodium-glucose cotransporter type 1, or SGLT1, and sodium-glucose cotransporter type 2, or SGLT2, in our target discovery efforts based on their discovery that mice lacking SGLT1, SGLT2 or both exhibited potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism in preclinical models. Preclinical studies of sotagliflozin demonstrated that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is in the phase 3 stage of development to treat Type 2 diabetes mellitus.
Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. Orally administered insulin brings with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.ORMD0801 is in the phase 3 stage of development to treat Type 2 diabetes mellitus.
LY3209590 “Basal insulin-Fc” is a large molecule comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is in Phase 2 stage of development for the treatment of Type2 diabetes.
The novel basal insulin HM12460A consists of an insulin analog (Insulin 115)conjugated to the human aglycosylated FC fragment via a small PEG linker and is developed for once-weekly administration HM12460A displays substantially prolonged pharmacokinetic and pharmacodynamic profile ,No increased mitogenic potency compared to regular insulin .It showed similar metabolic potency compared to regular insulin after long-term stimulation , decreased insulin receptor downregulation and it showed improved insulin signaling under chronic conditions.It is in Phase1 stage of development for the treatment of Type2 diabetes.
HM14220 is a combination of a long-acting insulin analog and a long-acting exendin-4 analog; Targeting once weekly administration. It is in the pre-clinical stage of development for the treatment of Type 2 Diabetes.
Type 2 Diabetes Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Lexicon Pharmaceuticals.
Request a sample and discover the recent advances in Type 2 Diabetes Ongoing Clinical Trial Analysis and Medications, click here @ Type 2 Diabetes Treatment Landscape
Scope of the Type 2 Diabetes Pipeline Insight Report
Dive deep into rich insights for drugs for Type 2 Diabetes Market Drivers and Type 2 Diabetes Market Barriers, click here @ Type 2 Diabetes Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Type 2 Diabetes Pipeline Mergers and acquisitions, Type 2 Diabetes Pipeline Licensing Activities @ Type 2 Diabetes Pipeline Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/